Ocular Allergy

Concurrent use of a beta-blocker with Simbrinza delayed the onset of ocular allergy and may extend treatment duration and adherence among patients with glaucoma, according to a retrospective study in BMC Ophthalmology.

More research is needed to improve diagnosis of dry eye disease in children, as well as to determine the safety and efficacy of treatment options in this population, according to a literature review published in The Ocular Surface.

NASHVILLE, Tenn. — Short-term noninvasive tear breakup time increased with use of Lumify eye drops in cohort of patients with and without dry eye disease, according to a poster presented at Optometry’s Meeting.

DENVER – Bilastine 0.6% ophthalmic solution was shown in a phase 3 trial to be comfortable and effective in patients with allergic conjunctivitis, Paul J. Gomes, of Ora Inc. said here at ARVO.

Ocular surface disease includes as major diagnoses dry eye disease, blepharitis/meibomian gland dysfunction and ocular allergy.

The American Society of Cataract and Refractive Surgery meeting moved to a virtual format this year due to the COVID-19 pandemic.

In this video perspective from the virtual American Society of Cataract and Refractive Surgery meeting, Ranjan P. Malhotra, MD, discusses how having Zerviate (cetirizine ophthalmic solution 0.24%, Eyevance) gives him another tool to prescribe patients for ocular itch during spring allergy season.

As long as I’m on the topic I got to thinking, do we really need another topical antihistamine drop? It’s a good time to ask because the rabble rousers at Eyevance have kicked their disruptive business model into high gear with the announcement of the Zerviate launch. As an aside, their answer to “do we need another topical steroid drop?” is the return of Tobradex ST.

The Institut National D’excellence en Santé et en Services Sociaux in Quebec has recommended the inclusion of Verkazia eye drops on the lists of drugs for the treatment of severe vernal keratoconjunctivitis, Santen Canada announced in a press release.

The first patient has been enrolled in a phase 3 trial of Aldeyra Therapeutics’ allergic conjunctivitis treatment candidate reproxalap, according to a press release.